Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 1 dose-escalation study with no results posted; establishes safety and feasibility of combined NK cell and bortezomib therapy in treatment-refractory cancers, but is early-stage and uncontrolled.